The estimated Net Worth of Matthew T Plavan is at least $52.6 Tisíc dollars as of 21 January 2021. Mr. Plavan owns over 585 units of Arcadia Biosciences Inc stock worth over $40,855 and over the last 18 years he sold RKDA stock worth over $11,744. In addition, he makes $0 as Chief Executive Officer a Director at Arcadia Biosciences Inc.
Matthew has made over 6 trades of the Arcadia Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 585 units of RKDA stock worth $1,849 on 21 January 2021.
The largest trade he's ever made was selling 17,271 units of Arcadia Biosciences Inc stock on 2 September 2015 worth over $11,744. On average, Matthew trades about 872 units every 73 days since 2007. As of 21 January 2021 he still owns at least 14,285 units of Arcadia Biosciences Inc stock.
You can see the complete history of Mr. Plavan stock trades at the bottom of the page.
Matthew T. Plavan , CPA is Chief Executive Officer, Director of the Company. He as appointed President of the Company’s new strategic business unit, Arcadia Specialty Genomics, in February 2019 and has served as our Chief Financial Officer since September 2016. Mr. Plavan brings over 30 years of financial and executive leadership experience to the Company in the areas of business operations, fiscal management and strategy, commercial partnering, M&A and integration activities, and public and private equity fundraising. Mr. Plavan served in multiple executive capacities, including CFO, COO, CEO, and board member with Cesca Therapeutics, Inc., a company engaged in research, development and commercialization of autologous cell-based therapeutics, from 2005 until 2015. Prior to that, Mr. Plavan held CFO positions with venture and private equity-backed technology companies, including StrionAir, Inc. from 2002 to 2005, and InPhonic, Inc. (formerly Reason Inc.) from 2000 to 2002. Mr. Plavan also held executive finance positions with McKesson Corporation from 1993 to 2000 and audit and advisory management positions with Ernst & Young from 1987 to 1993. Mr. Plavan is a California certified public accountant and earned a Bachelor of Arts degree in business economics from the University of California, Santa Barbara.
Matthew Plavan is 51, he's been the Chief Executive Officer a Director of Arcadia Biosciences Inc since 2019. There are 6 older and 4 younger executives at Arcadia Biosciences Inc. The oldest executive at Arcadia Biosciences Inc is Donald Emlay, 73, who is the Vice President - Regulatory Affairs and Compliance.
Matthew's mailing address filed with the SEC is C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS, CA, 95618.
Over the last 9 years, insiders at Arcadia Biosciences Inc have traded over $35,492 worth of Arcadia Biosciences Inc stock and bought 2,813,834 units worth $22,335,794 . The most active insiders traders include Terri Csperling Peter V Mor..., Darby E Shupp a Albert D. Bolles. On average, Arcadia Biosciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $147,899. The most recent stock trade was executed by Mark Kawakami on 1 August 2024, trading 700 units of RKDA stock currently worth $1,442.
arcadia biosciences (nasdaq: rkda) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. arcadia’s goodwheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. the company’s portfolio of agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. for more information visit www.arcadiabio.com.
Arcadia Biosciences Inc executives and other stock owners filed with the SEC include: